Medy-Tox Inc., South Korea’s leading botulinum toxin producer, has launched Coretox, a new botulinum toxin type A product aimed to reduce the risk of resistance, an ongoing concern after repeated injections.

It marks the third product in the company’s Botox lineup, following Medytoxin, the first locally developed Botox product, and Innotox, the world`s first liquid toxin formulation. Medy-Tox is the first in the world that has developed three types of Botox formulations.

The company said the reduced resistance of Coretox was obtained by eliminating non-toxic proteins that are not involved in efficacy and refining only neurotoxins. Patients can develop resistance to Botox treatment depending on the number of administration, duration, and dosage due to the nature of periodic injections.

In particular, Medy-Tox excluded animal components in the botulinum culture medium in the manufacturing process for the first time in the world and human serum albumin used as a stabilizer in the finished product to reduce the possibility of infection with blood-borne pathogens.

On the launch of Coretox, Medy-Tox plans to wage a massive campaign to publicize the risk of resistance to botulinum toxin treatment at domestic and international conferences and related events.

On Thursday, Kosdaq-listed Medy-Tox stocks were trading at 537,900 won ($478.18), down 0.35 percent, or 1,900 won, as of 11:14 a.m. in Seoul trading.

By Kim Byung-ho and Minu Kim

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]